Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 615

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 615
---
 to ensure that information required to be disclosed
by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s
management, including its principal executive and principal accounting officers, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its
judgment in evaluating the cost-benefit relationship of possible controls and procedures. The Certifying Officers have concluded, based
on their evaluation as of the end of the period covered by this Report, that our disclosure controls and procedures were effective
to provide reasonable assurance that the objectives of our disclosure control system were met.

Management’s
Annual Report on Internal Control over Financial Reporting

Management of the
Company is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Section 13a-15(f)
of the Securities Exchange Act of 1934, as amended). Internal control over financial reporting is a process designed by, or under
the supervision of, the Company’s principal financial officer to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of the Company’s financial statements for external reporting purposes in conformity with U.S. generally
accepted accounting principles and include those policies and procedures that (i) pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and
directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company’s assets that could have a material effect on the financial statements. During 2024, we designed
and implemented new and enhanced controls to strengthen our internal controls over financial reporting, including hiring additional experienced
accounting personnel, among other enhancements. Management believes these enhancements were sufficient to remediate previously identified
material weaknesses.

As of December 31, 2024, management
conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the framework established
in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the